These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3933225)

  • 21. [Derivation and experimental evaluation of polyvalent corpuscular vaccine for prevention of infections caused by Pseudomonas aeruginosa. I. Development of polyvalent corpuscular vaccine].
    Moroz AF; Radkevich SA; Antsiferova NG; Brodinova NS
    Zh Mikrobiol Epidemiol Immunobiol; 1981; (8):44-9. PubMed ID: 6171956
    [No Abstract]   [Full Text] [Related]  

  • 22. [Antigenic complexes of Pseudomonas aeruginosa slime: their isolation and biological properties].
    Aleksandrov AD; Antsiferova NG; Zhmyrina TI; Moroz AF
    Zh Mikrobiol Epidemiol Immunobiol; 1984 Jan; (1):14-9. PubMed ID: 6422680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
    Cryz SJ; Sadoff JC; Ohman D; Fürer E
    J Lab Clin Med; 1988 Jun; 111(6):701-7. PubMed ID: 3131471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cell-free Pseudomonas vaccine: its immunochemical characteristics and immunogenicity].
    Bandman OA; Edvabnaia LS; Bulk VF; Zhvanetskaia MI; Mashilova GM
    Zh Mikrobiol Epidemiol Immunobiol; 1987 Nov; (11):44-7. PubMed ID: 3124416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Results of using polyvalent Pseudomonas aeruginosa vaccine in children with burns by various medical centers].
    Bbukowska D; Serafińska D; Rudowski W; Hoffman S; Olański W; Gardzińska E; Popiel D; Jedrzejczak G; Czarnecka I
    Pol Tyg Lek; 1989 Oct 23-Nov 6; 44(43-45):924-7. PubMed ID: 2518666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immunological activity and toxicity of a peroral vaccine made from mutant Re Salmonella minnesota].
    Apollonin AV; Artemova EK; Vlasov GS; Kuklina SI; Salov VF
    Zh Mikrobiol Epidemiol Immunobiol; 1984 Mar; (3):78-82. PubMed ID: 6730810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase 1 trial of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously.
    Edelman R; Taylor DN; Wasserman SS; McClain JB; Cross AS; Sadoff JC; Que JU; Cryz SJ
    Vaccine; 1994 Nov; 12(14):1288-94. PubMed ID: 7856293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experimental immunization with Pseudomonas aeruginosa alginate induces IgA and IgG antibody responses.
    Johansen HK; Høiby N; Pedersen SS
    APMIS; 1991 Dec; 99(12):1061-8. PubMed ID: 1772641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of two immunization schedules for a Pseudomonas aeruginosa outer membrane proteins vaccine in burn patients.
    Kim DK; Kim JJ; Kim JH; Woo YM; Kim S; Yoon DW; Choi CS; Kim I; Park WJ; Lee N; Jung SB; Ahn BY; Nam SW; Yoon SM; Choi WJ
    Vaccine; 2000 Dec; 19(9-10):1274-83. PubMed ID: 11137267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical evaluation of an octavalent Pseudomonas aeruginosa conjugate vaccine in plasma donors and in bone marrow transplant and cystic fibrosis patients.
    Cryz SJ; Fürer E; Que JU; Sadoff JC; Brenner M; Schaad UB
    Antibiot Chemother (1971); 1991; 44():157-62. PubMed ID: 1801634
    [No Abstract]   [Full Text] [Related]  

  • 31. Evaluation of the immune responses following co-administration of PilQ and type b-flagellin from Pseudomonas aeruginosa in the burn mouse model.
    Bakht Azad S; Nikokar I; Faezi S; Rasooly S; Mahdavi M
    Microb Pathog; 2018 Oct; 123():426-432. PubMed ID: 30075242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cell-free Pseudomonas vaccine. IV. Laboratory trials of the effectiveness of experimental Pseudomonas vaccines].
    Stanislavskiĭ ES; Joó I; Bulk VF; Zhvanetskaia MI; Mashilova GM
    Zh Mikrobiol Epidemiol Immunobiol; 1982 Oct; (10):25-9. PubMed ID: 6817559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of a polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A vaccine in humans.
    Cryz SJ; Sadoff JC; Cross AS; Fürer E
    Antibiot Chemother (1971); 1989; 42():177-83. PubMed ID: 2512836
    [No Abstract]   [Full Text] [Related]  

  • 34. [Experimentally determined safety and immunological activity of vaccine based on antigens isolated from Pseudomonas aeruginosa in medium K-4].
    Nuriddinova NR; Sheremet'ev NN; Ivanova LE; Garib FIu; Iskhakova KhI
    Zh Mikrobiol Epidemiol Immunobiol; 2005; (3):57-60. PubMed ID: 16028515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The safety, reactogenicity and antigenic activity of a Pseudomonas aeruginosa anatoxin studied in volunteers].
    Mikhaĭlova NA; Kuniagina OV; Kuznetsova TN; Sadykova AF; Brodinova NS; Bodrova GN
    Zh Mikrobiol Epidemiol Immunobiol; 1995; (3):89-92. PubMed ID: 7660711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Catalase immunization from Pseudomonas aeruginosa enhances bacterial clearance in the rat lung.
    Thomas LD; Dunkley ML; Moore R; Reynolds S; Bastin DA; Kyd JM; Cripps AW
    Vaccine; 2000 Sep; 19(2-3):348-57. PubMed ID: 10930690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The effect of an immune antibacterial plasma and a donor leukocyte mass on the immune system of patients with suppurative-septic processes].
    Bulava GV; Zdanovskaia LK; Titova TI
    Zh Mikrobiol Epidemiol Immunobiol; 1989 Oct; (10):91-6. PubMed ID: 2514532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccines against Pseudomonas aeruginosa infection: 2. Clinico-immunological investigations.
    Krokhina MA; Grishina IA; Panova YuM ; Terekhova RP; Severtsova MK; Yedvabnaya LS; Vaide M; Varro R; Rusanov VM; Kolker II
    Vaccine; 1985 Sep; 3(3):316-24. PubMed ID: 3933202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of experimental burn wound sepsis by postburn immunization with polyvalent Pseudomonas antigen.
    Nance FC; Hines JL; Fulton RE; Bornside GH
    Surgery; 1970 Jul; 68(1):248-53. PubMed ID: 10483476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Evaluation of the immunological activity of a vaccine from mutant Salmonella minnesota R 595 on a model of experimental Pseudomonas aeruginosa infection in mice].
    Likhoded VG; Apollonin AV; Gremiakova TA; Artemova EK
    Zh Mikrobiol Epidemiol Immunobiol; 1983 Apr; (4):103-6. PubMed ID: 6408854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.